Effects of acute and chronic nicotine on elevated plus maze in mice: Involvement of calcium channels

被引:31
|
作者
Biala, Grazyna [1 ]
Budzynska, Barbara [1 ]
机构
[1] Med Univ Lublin, Dept Pharmacol & Pharmacodynam, PL-20081 Lublin, Poland
关键词
nicotine; anxiety; calcium channel antagonists; elevated plus maze; mice;
D O I
10.1016/j.lfs.2005.12.043
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The current experiments examined the anxiety-related effects of acute and repeated nicotine administration using the elevated plus maze test in mice. Nicotine (0.1 mg/kg s.c., 5 and 30 min after injection; 0.5 mg/kg, s.c., 5 min after injection) had an anxiogenic effect, shown by specific decreases in the percentage of time spent on the open arms and in the percentage of open arm entries. Tolerance developed to this anxiogenic action after 6 days of daily nicotine administration (0.1 mg/kg, s.c.). Five minutes after the seventh injection, an anxiolytic effect was observed, i.e., specific increases in the percentage of time spent on the open arms and in the percentage of open arm entries. L-type voltage-dependent calcium channel antagonists nimodipine (5 and 10 mg/kg, i.p.), flunarizine (5 and 10 mg/kg, i.p.), verapamil (5, 10, 20 mg/kg) and diltiazem (5, 10, 20 mg/kg, i.p.) were also injected prior to an acute low dose of nicotine or to each injection of chronic nicotine. Our results revealed that calcium channel blockers dose-dependently attenuated both an anxiogenic effect of nicotine as well as the development of tolerance to this effect. Our results suggest that neural calcium-dependent mechanisms are involved in the anxiety-related responses to acute and chronic nicotine injection that may ultimately lead to addiction and smoking relapse in human smokers. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 50 条
  • [1] ETHOLOGICAL COMPARISON OF THE EFFECTS OF DIAZEPAM AND ACUTE CHRONIC IMIPRAMINE ON THE BEHAVIOR OF MICE IN THE ELEVATED PLUS-MAZE
    COLE, JC
    RODGERS, RJ
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1995, 52 (03) : 473 - 478
  • [2] Acute and subchronic effects of agmatine on anxiety tested in the elevated plus maze in male mice
    Navarro, JF
    Luna, G
    García, FB
    PSICOTHEMA, 2005, 17 (03) : 492 - 495
  • [3] Influence of bupropion and calcium channel antagonists on the memory-related response induced by nicotine in the elevated plus maze in mice
    Kruk, Marta
    Budzynska, Barbara
    Biala, Grayna
    PHARMACOLOGICAL REPORTS, 2007, 59 : 37 - 37
  • [4] Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice
    Biala, Grazyna
    Kruk, Marta
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (04) : 493 - 502
  • [5] Cannabinoid receptor ligands suppress memory-related effects of nicotine in the elevated plus maze test in mice
    Biala, Grazyna
    Kruk, Marta
    BEHAVIOURAL BRAIN RESEARCH, 2008, 192 (02) : 198 - 202
  • [6] The involvement of adenosine receptors in the effect of dizocilpine on mice in the elevated plus-maze
    Fraser, CM
    Fisher, A
    Cooke, MJ
    Thompson, ID
    Stone, TW
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (04) : 267 - 273
  • [7] Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice
    Carrasco, MC
    Vicens, P
    Vidal, J
    Redolat, R
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (07): : 1135 - 1141
  • [8] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze
    Biała G.
    Kruk M.
    Pharmacological Reports, 2009, 61 (2) : 236 - 244
  • [9] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze
    Biala, Grazyna
    Kruk, Marta
    PHARMACOLOGICAL REPORTS, 2009, 61 (02) : 236 - 244
  • [10] Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice
    Liu, Junhan
    Scott, Brian W.
    Burnham, Willets McIntyre
    BEHAVIOURAL PHARMACOLOGY, 2022, 33 (2-3): : 206 - 212